Breakthrough
Technology.
Transforming Drug Discovery.

Drug discovery is a long, expensive, and complex process. Our suite of groundbreaking protein footprinting technologies make for faster, more accurate, and more efficient characterization. That translates into better data, lower costs, and faster turnaround time.

The Multi-Billion Dollar Bottleneck.

Drug developers need every advantage to ensure their time, effort, and investment result in a successful, first-in-class product.

13.5 years

from discovery to development

$1.8 billion

to bring a therapeutic to market

Only 8%

of therapeutic candidates make it through candidate selection

The Solution

A New Paradigm in Drug Discovery.

Protein structural analysis is an essential step in the drug discovery process, and compared to all other methods used today, our suite of proprietary technologies enables developers to investigate interactions of therapeutics and their targets with an unprecedented degree of accuracy and speed.

That means significantly reducing uncertainty —  and the costs related to it.

Novel Epitope Mapping:

Unlike other methods, our groundbreaking suite of  technologies for the first time makes it possible to map epitopes and paratopes quickly, reliably through a native, in-solution analysis.

Protein Small Molecule Interaction:
  • Gain detailed insights into ligand-protein interactions.
  • Pinpoint amino acid level hotspots to locate binding interactions.
  • Generate a detailed map of ligand-induced higher-order structural changes.
Protein-Protein Interaction:
  • Protein-Protein Interaction:
  • Characterize drug/receptor interactions, protein aggregation, or dimerization.
Protein Higher Order Structure:
  • Characterize and detect subtle differences in protein higher order structure (HOS).
  • Use HOS for measuring comparability studies for characterizing biosimilar-innovator differences, expression platforms, formulation, or changes based on buffer or environmental conditions.

Lead Optimization.
Optimized.

We partner with pharmaceutical companies in drug discovery to streamline their lead optimization, helping to reduce cycle times, increase lead candidates, and maximize the probability of drug success leading up to clinical trials.

Quick Turnaround:

Get results  in 2–3 weeks to perform rapid lead optimization iteration

Reduce Cost:

Can be performed on many lead candidates simultaneously

Native Analysis:

Native structure and protein conditions for biologically-relevant results

Faster IP Filings:

Better epitope findings earlier make for stronger claims

Protein Compatibility:

Can be used to analyze challenging protein targets

Introducing PLIMB:

Rapid High-Resolution Analysis

Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.

PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.

Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.

PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.

No lengthy protein crystallization required
Performed in biologically-relevant buffer
Requires minimal sample sizes (>5ug per sample)
High throughputs for multiple, synchronous targeting
Analyzes proteins incompatible with other techniques
Prevents denaturization through sub-microsecond timescale

The Proof Is in the Papers.

Our findings have been published in some of the most prestigious peer-reviewed journals. Your therapeutics save lives. We save you time and resources.

In Good Company

Get In Touch.

Your therapeutics save lives.
We save you time and resources.

Let's Talk

© Copyright 2021 Immuto Scientific. All rights reserved.

Breakthrough
Technology.
Transforming Drug Discovery.

Drug discovery is a long, expensive, and complex process. Our suite of groundbreaking protein footprinting technologies make for faster, more accurate, and more efficient characterization. That translates into better data, lower costs, and faster turnaround time.

The Multi-Billion Dollar Bottleneck.

Drug developers need every advantage to ensure their time, effort, and investment result in a successful, first-in-class product.

13.5 years

from discovery to development

$1.8 billion

to bring a therapeutic to market

Only 8%

of therapeutic candidates make it through candidate selection

The Solution

A New Paradigm in Drug Discovery.

Protein structural analysis is an essential step in the drug discovery process, and compared to all other methods used today, our suite of proprietary technologies enables developers to investigate interactions of therapeutics and their targets with an unprecedented degree of accuracy and speed.

That means significantly reducing uncertainty —  and the costs related to it.

Novel Epitope Mapping:

Unlike other methods, our groundbreaking suite of  technologies for the first time makes it possible to map epitopes and paratopes quickly, reliably through a native, in-solution analysis.

Protein Small Molecule Interaction:
  • Gain detailed insights into ligand-protein interactions.
  • Pinpoint amino acid level hotspots to locate binding interactions.
  • Generate a detailed map of ligand-induced higher-order structural changes.
Protein-Protein Interaction:
  • Map the specific regions of interactions between proteins.
  • Characterize drug/receptor interactions, protein aggregation, or dimerization.
Protein Higher Order Structure:
  • Characterize and detect subtle differences in protein higher order structure (HOS).
  • Use HOS for measuring comparability studies for characterizing biosimilar-innovator differences, expression platforms, formulation, or changes based on buffer or environmental conditions.

Lead Optimization.
Optimized.

We partner with pharmaceutical companies in drug discovery to streamline their lead optimization, helping to reduce cycle times, increase lead candidates, and maximize the probability of drug success leading up to clinical trials.

Quick Turnaround

Get results  in 2–3 weeks to perform rapid lead optimization iteration

Cost Reduction

Can be performed on many lead candidates simultaneously

Native Analysis

Native structure and protein conditions for biologically-relevant results

Faster IP Filings

Better epitope findings earlier make for stronger claims

Protein Compatibility

Can be used to analyze challenging protein targets

Introducing PLIMB:

Rapid High-Resolution Analysis

Our core proprietary technology, PLIMB (Plasma Induced Modification of Biomolecules) is setting a new standard for epitope mapping and structural analysis.

PLIMB provides high-resolution data on antibody binding while eliminating other costly inefficiencies, so developers can zero-in on multiple high-probability leads at the same time.

No lengthy protein crystallization required
Performed in biologically-relevant buffer
Requires minimal sample sizes (>5ug per sample)
High throughputs for multiple, synchronous targeting
Analyzes proteins incompatible with other techniques
Prevents denaturization through sub-microsecond timescale

The World Needs Pharma. Pharma Needs Us.

Our team is made up of leading scientists and researchers boasting a collective 20+ years of experience in protein biochemistry, mass spectrometry, and drug discovery and development. Our state-of-the-art technologies and expertise are changing drug discovery as we know it.

Therapeutic Areas / Disease Understanding
Candidate Selection
Discovery / Screening Efforts
Process / Analytical Methods Development

The Proof Is in the Papers.

Our findings have been published in some of the most prestigious peer-reviewed journals. Your therapeutics save lives. We save you time and resources.

In Good Company.

We’ve attracted the attention of industry leaders, investors, and clients, including the top pharmaceutical companies and biotechnology firms in the US, and these esteemed institutional partners.

University of Wisconsin Madison

Wisconsin Alumni Research Foundation

National Science Foundation

Wisconsin Investment Partners

Milwaukee Venture Partners

National Institute of Health

Let's Talk